-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, April 15 Respiratory system disease is a common and frequently-occurring disease.
The latest data from Mi Nei.
com shows that in 2020, the sales of Chinese patent medicines for the respiratory system of public hospitals in key cities have declined year-on-year.
In terms of urban structure, Beijing, Chengdu, and Harbin are among the top three.
Among the TOP20 products, 6 products have sales of more than 100 million yuan; 14 are exclusive products, involving Yangtze River Beijing Haiyan Pharmaceutical, Tianjin Hongri Pharmaceutical, Jichuan Pharmaceutical Group, Beijing Yiling Pharmaceutical and other companies In terms of growth rate, Shuanghuanglian oral liquid and Lianhua Qingwen granules both increased by more than 50% year-on-year.
Since 2020, 4 proprietary Chinese medicines for the respiratory system have been approved for listing.
Jiangsu Kangyuan Pharmaceutical's Yinqiao Qingre Tablets, Hubei Youersheng Pharmaceutical's Tianxing Cough Paste, and Shenzhen Sanshun Pharmaceutical's Caohong Capsules have submitted new drugs for listing.
All applications are under review and approval.
The latest data from Mi Nei.
com shows that in 2020, the sales of Chinese patent medicines for the respiratory system of public hospitals in key cities have declined year-on-year.
In terms of urban structure, Beijing, Chengdu, and Harbin are among the top three.
Among the TOP20 products, 6 products have sales of more than 100 million yuan; 14 are exclusive products, involving Yangtze River Beijing Haiyan Pharmaceutical, Tianjin Hongri Pharmaceutical, Jichuan Pharmaceutical Group, Beijing Yiling Pharmaceutical and other companies In terms of growth rate, Shuanghuanglian oral liquid and Lianhua Qingwen granules both increased by more than 50% year-on-year.
Since 2020, 4 proprietary Chinese medicines for the respiratory system have been approved for listing.
Jiangsu Kangyuan Pharmaceutical's Yinqiao Qingre Tablets, Hubei Youersheng Pharmaceutical's Tianxing Cough Paste, and Shenzhen Sanshun Pharmaceutical's Caohong Capsules have submitted new drugs for listing.
All applications are under review and approval.
Chinese patent medicines for respiratory system are selling well in Beijing! The market share of the three major sub-categories exceeds 90%
Quarterly sales of proprietary Chinese medicines for respiratory system in public hospitals in key cities in recent years
Source: Competitive pattern of proprietary Chinese medicine terminals in public hospitals in key cities
According to data from Mi Nei.
com, in recent years, the sales of Chinese patent medicines for the respiratory system of public hospitals in key cities have exceeded 3.
5 billion yuan.
In 2020, affected by the epidemic, it will drop 20% year-on-year.
In terms of quarterly sales trends, both Q1 and Q2 fell more than 25% year-on-year in 2020.
The market gradually recovered in the second half of the year.
Q3 fell 15.
96% year-on-year, and Q4 has been significantly reduced to 4.
59%.
com, in recent years, the sales of Chinese patent medicines for the respiratory system of public hospitals in key cities have exceeded 3.
5 billion yuan.
In 2020, affected by the epidemic, it will drop 20% year-on-year.
In terms of quarterly sales trends, both Q1 and Q2 fell more than 25% year-on-year in 2020.
The market gradually recovered in the second half of the year.
Q3 fell 15.
96% year-on-year, and Q4 has been significantly reduced to 4.
59%.
The urban pattern of Chinese patent medicines for the respiratory system of public hospitals in key cities in 2020
Source: Competitive pattern of proprietary Chinese medicine terminals in public hospitals in key cities
From the perspective of the urban structure, Beijing's sales are thriving, exceeding 600 million yuan; Chengdu and Harbin both exceed 400 million yuan.
From the perspective of sub-categories, the three major sub-categories of heat-clearing and detoxifying medications, cough-relieving and anti-asthmatic medications, and cold medications have a combined market share of more than 95%.
From the perspective of sub-categories, the three major sub-categories of heat-clearing and detoxifying medications, cough-relieving and anti-asthmatic medications, and cold medications have a combined market share of more than 95%.
Yangtze River, Yiling.
.
.
14 exclusive products "seize" TOP20
.
.
14 exclusive products "seize" TOP20
Top 10 Chinese patent medicine products for respiratory system in public hospitals in key cities in 2020
Source: Competitive pattern of proprietary Chinese medicine terminals in public hospitals in key cities
Among the TOP20 products, six products have sales of more than 100 million yuan.
Suhuang Cough Capsules, Xuebijing Injection, Pudilan Anti-inflammatory Oral Liquid, Lianhua Qingwen Granules and other 14 are exclusive products, involving Yangtze River Beijing Haiyan Pharmaceutical, Tianjin Hongri Pharmaceutical, Jichuan Pharmaceutical Group, Beijing Ling Pharmaceutical and many other enterprises .
In terms of growth rate, Shuanghuanglian Oral Liquid and Lianhua Qingwen Granules both increased by more than 50% year-on-year.
It is worth mentioning that Shuanghuanglian oral liquid, Shufeng Jiedu capsule, cough and asthma syrup are all new products on the list.
Suhuang Cough Capsules, Xuebijing Injection, Pudilan Anti-inflammatory Oral Liquid, Lianhua Qingwen Granules and other 14 are exclusive products, involving Yangtze River Beijing Haiyan Pharmaceutical, Tianjin Hongri Pharmaceutical, Jichuan Pharmaceutical Group, Beijing Ling Pharmaceutical and many other enterprises .
In terms of growth rate, Shuanghuanglian Oral Liquid and Lianhua Qingwen Granules both increased by more than 50% year-on-year.
It is worth mentioning that Shuanghuanglian oral liquid, Shufeng Jiedu capsule, cough and asthma syrup are all new products on the list.
2020 Top 10 Chinese Patent Medicine Brands for Respiratory System in Public Hospitals in Key Cities
Source: Competitive pattern of proprietary Chinese medicine terminals in public hospitals in key cities
The total market share of TOP20 brands exceeds 60%.
Among them, Suhuang Cough Capsules from Yangtze River Beijing Haiyan Pharmaceutical, Xiyanping Injection from Jiangxi Qingfeng Pharmaceutical, and Tanreqing Injection from Shanghai Kaibao Pharmaceutical rank among the top three.
.
Among them, Suhuang Cough Capsules from Yangtze River Beijing Haiyan Pharmaceutical, Xiyanping Injection from Jiangxi Qingfeng Pharmaceutical, and Tanreqing Injection from Shanghai Kaibao Pharmaceutical rank among the top three.
.
Sales of Shuanghuanglian Oral Liquid in Public Hospitals in Key Cities in Recent Years
Source: Competitive pattern of proprietary Chinese medicine terminals in public hospitals in key cities
Shuanghuanglian oral liquid has the effects of dispelling wind, relieving the surface, clearing heat and detoxifying, and is used for colds caused by exogenous wind-heat, such as fever, cough and sore throat.
According to data from Meinenet, the sales of Shuanghuanglian oral liquid in public hospitals in key cities have increased rapidly in the past two years , and the year-on-year growth rate will reach nearly 70% in 2020.
There are 12 companies with production approvals for this product.
Among them, Heilongjiang Regal Pharmaceutical has the largest market share, exceeding 60%, and Henan Tailong Pharmaceutical ranks second.
According to data from Meinenet, the sales of Shuanghuanglian oral liquid in public hospitals in key cities have increased rapidly in the past two years , and the year-on-year growth rate will reach nearly 70% in 2020.
There are 12 companies with production approvals for this product.
Among them, Heilongjiang Regal Pharmaceutical has the largest market share, exceeding 60%, and Henan Tailong Pharmaceutical ranks second.
Sales of Lianhua Qingwen Granules in Public Hospitals in Key Cities in Recent Years
Source: Competitive pattern of proprietary Chinese medicine terminals in public hospitals in key cities
Lianhua Qingwen Granules is an exclusive product of Ling Pharmaceutical.
According to data from Minaiwang, the sales of Lianhua Qingwen Granules in public hospitals in key cities have maintained a growth rate of more than 20% in recent years, and will reach a new high in 2020.
A few days ago, Yiling Pharmaceutical disclosed its performance in 2020, with revenue of 8.
78 billion yuan, a year-on-year increase of 50.
76%; net profit of 1.
219 billion yuan, a year-on-year increase of 100.
95%.
Yiling Pharmaceutical pointed out in the annual report that Lianhua Qingwen products played an important role in the prevention and control of the epidemic, which not only drove the substantial increase in product sales, but also increased the coverage of the blank market structurally, and the brand influence was significantly improved.
With strong market demand, it has become a regular backup drug for many families, providing impetus for its future growth.
At the same time, Lianhua Qingwen has obtained approvals and achieved sales in more than 20 countries and regions.
According to data from Minaiwang, the sales of Lianhua Qingwen Granules in public hospitals in key cities have maintained a growth rate of more than 20% in recent years, and will reach a new high in 2020.
A few days ago, Yiling Pharmaceutical disclosed its performance in 2020, with revenue of 8.
78 billion yuan, a year-on-year increase of 50.
76%; net profit of 1.
219 billion yuan, a year-on-year increase of 100.
95%.
Yiling Pharmaceutical pointed out in the annual report that Lianhua Qingwen products played an important role in the prevention and control of the epidemic, which not only drove the substantial increase in product sales, but also increased the coverage of the blank market structurally, and the brand influence was significantly improved.
With strong market demand, it has become a regular backup drug for many families, providing impetus for its future growth.
At the same time, Lianhua Qingwen has obtained approvals and achieved sales in more than 20 countries and regions.
According to the data, in the fourth to eighth editions of the "Diagnosis and Treatment Plan for Pneumonia Infected by New Coronavirus", it is recommended to take the Chinese patent medicine Lianhua Qingwen for the prevention and treatment of patients with fatigue and fever during the medical observation period.
More than 20 provinces and cities such as Hubei, Guangzhou, Zhejiang, Shandong, Hebei and other provinces and cities have successively released new coronary pneumonia prevention and treatment plans, and Lianhua Qingwen is also recommended.
The "three medicines and three prescriptions" screened for effective drugs for the treatment of new coronary pneumonia in Chinese medicine include Lianhua Qingwen capsules/granules.
In April 2020, Lianhua Qingwen capsules/granules were approved to add new indications of "New Coronavirus Pneumonia Light and Common" on the basis of the original approved indications.
More than 20 provinces and cities such as Hubei, Guangzhou, Zhejiang, Shandong, Hebei and other provinces and cities have successively released new coronary pneumonia prevention and treatment plans, and Lianhua Qingwen is also recommended.
The "three medicines and three prescriptions" screened for effective drugs for the treatment of new coronary pneumonia in Chinese medicine include Lianhua Qingwen capsules/granules.
In April 2020, Lianhua Qingwen capsules/granules were approved to add new indications of "New Coronavirus Pneumonia Light and Common" on the basis of the original approved indications.
4 products have been approved since 2020 ! 3 major new drugs launched an impact
Review of applications for the listing of Chinese patent medicines for respiratory system since 2020
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since 2020, a total of 4 Chinese patent medicines for respiratory system have been approved for production.
In May 2020, Yiling Pharmaceutical’s Lianhua Qingke Tablets was approved to be marketed.
This product is a new class of 6.
1 new Chinese medicine for the treatment of acute tracheal-bronchitis developed under the guidance of TCM collateral disease theory.
The cumulative R&D investment exceeds 20 million yuan; In December, Lianhua Qingke Tablets were included in the 2020 National Medical Insurance Catalogue for the first time through medical insurance negotiations.
In March of this year, the State Food and Drug Administration approved the listing of Qingfei Paidu Granules from the Institute of Basic Clinical Medicine of Chinese Academy of Chinese Medical Sciences, Huashibaidu Granules of Guangdong Yifang Pharmaceutical, and Xuanfeibaidu Granules of Shandong Buchang Pharmaceutical through special approval procedures.
.
The three products are the results of the effective prescriptions Qingfei Paidu Decoction, Huashi Baidu Recipe, and Xuanfei Baidu Recipe screened by many academicians and experts in the anti-epidemic clinical front-line in Wuhan.
They are also the first time after the reform of Chinese medicine registration classification according to the "Chinese medicine registration classification and Application materials requirements" "Class 3.
2 other traditional Chinese medicine compound preparations derived from ancient classic prescriptions" review and approval varieties.
In May 2020, Yiling Pharmaceutical’s Lianhua Qingke Tablets was approved to be marketed.
This product is a new class of 6.
1 new Chinese medicine for the treatment of acute tracheal-bronchitis developed under the guidance of TCM collateral disease theory.
The cumulative R&D investment exceeds 20 million yuan; In December, Lianhua Qingke Tablets were included in the 2020 National Medical Insurance Catalogue for the first time through medical insurance negotiations.
In March of this year, the State Food and Drug Administration approved the listing of Qingfei Paidu Granules from the Institute of Basic Clinical Medicine of Chinese Academy of Chinese Medical Sciences, Huashibaidu Granules of Guangdong Yifang Pharmaceutical, and Xuanfeibaidu Granules of Shandong Buchang Pharmaceutical through special approval procedures.
.
The three products are the results of the effective prescriptions Qingfei Paidu Decoction, Huashi Baidu Recipe, and Xuanfei Baidu Recipe screened by many academicians and experts in the anti-epidemic clinical front-line in Wuhan.
They are also the first time after the reform of Chinese medicine registration classification according to the "Chinese medicine registration classification and Application materials requirements" "Class 3.
2 other traditional Chinese medicine compound preparations derived from ancient classic prescriptions" review and approval varieties.
In addition, Jiangsu Kangyuan Pharmaceutical's Yinqiao Qingre Tablets, Hubei Youersheng Pharmaceutical's Tianxing Cough Paste, and Shenzhen Sanshun Pharmaceutical's Caohong Capsules submitted new drug listing applications for approval.
Source: Mi Nei.
com database, announcement of listed companies
com database, announcement of listed companies
Note: The Chinese patent medicine terminal competition pattern database of public hospitals in key cities of Minaiwang is a sales database that continuously monitors the entire category of Chinese patent medicines based on the pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement data of Chinese patent medicines from all public hospitals in 9 major cities .
The data covers 13 categories.
More than 74 sub-categories, 3600+ common name varieties.
The database is updated quarterly to provide timely feedback on the impact of policy changes on products, and analyze the sales, market shares, sales trends and development laws of various categories and varieties of Chinese patent medicines in 9 cities in all categories in an all-round and multi-dimensional manner.
com.
cn/news/yyzb/" target="_blank">procurement data of Chinese patent medicines from all public hospitals in 9 major cities .
The data covers 13 categories.
More than 74 sub-categories, 3600+ common name varieties.
The database is updated quarterly to provide timely feedback on the impact of policy changes on products, and analyze the sales, market shares, sales trends and development laws of various categories and varieties of Chinese patent medicines in 9 cities in all categories in an all-round and multi-dimensional manner.
Medical Network News, April 15 Respiratory system disease is a common and frequently-occurring disease.
The latest data from Mi Nei.
com shows that in 2020, the sales of Chinese patent medicines for the respiratory system of public hospitals in key cities have declined year-on-year.
In terms of urban structure, Beijing, Chengdu, and Harbin are among the top three.
Among the TOP20 products, 6 products have sales of more than 100 million yuan; 14 are exclusive products, involving Yangtze River Beijing Haiyan Pharmaceutical, Tianjin Hongri Pharmaceutical, Jichuan Pharmaceutical Group, Beijing Yiling Pharmaceutical and other companies In terms of growth rate, Shuanghuanglian oral liquid and Lianhua Qingwen granules both increased by more than 50% year-on-year.
Since 2020, 4 proprietary Chinese medicines for the respiratory system have been approved for listing.
Jiangsu Kangyuan Pharmaceutical's Yinqiao Qingre Tablets, Hubei Youersheng Pharmaceutical's Tianxing Cough Paste, and Shenzhen Sanshun Pharmaceutical's Caohong Capsules have submitted new drugs for listing.
All applications are under review and approval.
The latest data from Mi Nei.
com shows that in 2020, the sales of Chinese patent medicines for the respiratory system of public hospitals in key cities have declined year-on-year.
In terms of urban structure, Beijing, Chengdu, and Harbin are among the top three.
Among the TOP20 products, 6 products have sales of more than 100 million yuan; 14 are exclusive products, involving Yangtze River Beijing Haiyan Pharmaceutical, Tianjin Hongri Pharmaceutical, Jichuan Pharmaceutical Group, Beijing Yiling Pharmaceutical and other companies In terms of growth rate, Shuanghuanglian oral liquid and Lianhua Qingwen granules both increased by more than 50% year-on-year.
Since 2020, 4 proprietary Chinese medicines for the respiratory system have been approved for listing.
Jiangsu Kangyuan Pharmaceutical's Yinqiao Qingre Tablets, Hubei Youersheng Pharmaceutical's Tianxing Cough Paste, and Shenzhen Sanshun Pharmaceutical's Caohong Capsules have submitted new drugs for listing.
All applications are under review and approval.
Chinese patent medicines for respiratory system are selling well in Beijing! The market share of the three major sub-categories exceeds 90%
Quarterly sales of proprietary Chinese medicines for respiratory system in public hospitals in key cities in recent years
Source: Competitive pattern of proprietary Chinese medicine terminals in public hospitals in key cities
According to data from Mi Nei.
com, in recent years, the sales of Chinese patent medicines for the respiratory system of public hospitals in key cities have exceeded 3.
5 billion yuan.
In 2020, affected by the epidemic, it will drop 20% year-on-year.
In terms of quarterly sales trends, both Q1 and Q2 fell more than 25% year-on-year in 2020.
The market gradually recovered in the second half of the year.
Q3 fell 15.
96% year-on-year, and Q4 has been significantly reduced to 4.
59%.
com, in recent years, the sales of Chinese patent medicines for the respiratory system of public hospitals in key cities have exceeded 3.
5 billion yuan.
In 2020, affected by the epidemic, it will drop 20% year-on-year.
In terms of quarterly sales trends, both Q1 and Q2 fell more than 25% year-on-year in 2020.
The market gradually recovered in the second half of the year.
Q3 fell 15.
96% year-on-year, and Q4 has been significantly reduced to 4.
59%.
The urban pattern of Chinese patent medicines for the respiratory system of public hospitals in key cities in 2020
Source: Competitive pattern of proprietary Chinese medicine terminals in public hospitals in key cities
From the perspective of the urban structure, Beijing's sales are thriving, exceeding 600 million yuan; Chengdu and Harbin both exceed 400 million yuan.
From the perspective of sub-categories, the three major sub-categories of heat-clearing and detoxifying medications, cough-relieving and anti-asthmatic medications, and cold medications have a combined market share of more than 95%.
From the perspective of sub-categories, the three major sub-categories of heat-clearing and detoxifying medications, cough-relieving and anti-asthmatic medications, and cold medications have a combined market share of more than 95%.
Yangtze River, Yiling.
.
.
14 exclusive products "seize" TOP20
.
.
14 exclusive products "seize" TOP20
Top 10 Chinese patent medicine products for respiratory system in public hospitals in key cities in 2020
Source: Competitive pattern of proprietary Chinese medicine terminals in public hospitals in key cities
Among the TOP20 products, six products have sales of more than 100 million yuan.
Suhuang Cough Capsules, Xuebijing Injection, Pudilan Anti-inflammatory Oral Liquid, Lianhua Qingwen Granules and other 14 are exclusive products, involving Yangtze River Beijing Haiyan Pharmaceutical, Tianjin Hongri Pharmaceutical, Jichuan Pharmaceutical Group, Beijing Ling Pharmaceutical and many other enterprises .
In terms of growth rate, Shuanghuanglian Oral Liquid and Lianhua Qingwen Granules both increased by more than 50% year-on-year.
It is worth mentioning that Shuanghuanglian oral liquid, Shufeng Jiedu capsule, cough and asthma syrup are all new products on the list.
Suhuang Cough Capsules, Xuebijing Injection, Pudilan Anti-inflammatory Oral Liquid, Lianhua Qingwen Granules and other 14 are exclusive products, involving Yangtze River Beijing Haiyan Pharmaceutical, Tianjin Hongri Pharmaceutical, Jichuan Pharmaceutical Group, Beijing Ling Pharmaceutical and many other enterprises .
In terms of growth rate, Shuanghuanglian Oral Liquid and Lianhua Qingwen Granules both increased by more than 50% year-on-year.
It is worth mentioning that Shuanghuanglian oral liquid, Shufeng Jiedu capsule, cough and asthma syrup are all new products on the list.
2020TOP10
：
TOP2060%，，、、。
：
、，，、、。，，202070%。12，，，60%，。
：
，，20%，2020。，2020，87.
82，50.
76%；12.
19，100.
95%。，，，，，，，，20。
82，50.
76%；12.
19，100.
95%。，，，，，，，，20。
，《》，。、、、、20，。“”/。20204，/，“、”。
20204！3
2020
：MED2.
0
0
2020，4。20205，，-6.
1，2000；12，2020。3，、、。、、，《》“3.
2”。
1，2000；12，2020。3，、、。、、，《》“3.
2”。
，、、。
：、
：9pharmnet.
com.
cn/news/yyzb/" target="_blank">，，13，74，3600+。，，9、、。
com.
cn/news/yyzb/" target="_blank">，，13，74，3600+。，，9、、。
Medical Network News, April 15 Respiratory system disease is a common and frequently-occurring disease.
The latest data from Mi Nei.
com shows that in 2020, the sales of Chinese patent medicines for the respiratory system of public hospitals in key cities have declined year-on-year.
In terms of urban structure, Beijing, Chengdu, and Harbin are among the top three.
Among the TOP20 products, 6 products have sales of more than 100 million yuan; 14 are exclusive products, involving Yangtze River Beijing Haiyan Pharmaceutical, Tianjin Hongri Pharmaceutical, Jichuan Pharmaceutical Group, Beijing Yiling Pharmaceutical and other companies In terms of growth rate, Shuanghuanglian oral liquid and Lianhua Qingwen granules both increased by more than 50% year-on-year.
Since 2020, 4 proprietary Chinese medicines for the respiratory system have been approved for listing.
Jiangsu Kangyuan Pharmaceutical's Yinqiao Qingre Tablets, Hubei Youersheng Pharmaceutical's Tianxing Cough Paste, and Shenzhen Sanshun Pharmaceutical's Caohong Capsules have submitted new drugs for listing.
All applications are under review and approval.
The latest data from Mi Nei.
com shows that in 2020, the sales of Chinese patent medicines for the respiratory system of public hospitals in key cities have declined year-on-year.
In terms of urban structure, Beijing, Chengdu, and Harbin are among the top three.
Among the TOP20 products, 6 products have sales of more than 100 million yuan; 14 are exclusive products, involving Yangtze River Beijing Haiyan Pharmaceutical, Tianjin Hongri Pharmaceutical, Jichuan Pharmaceutical Group, Beijing Yiling Pharmaceutical and other companies In terms of growth rate, Shuanghuanglian oral liquid and Lianhua Qingwen granules both increased by more than 50% year-on-year.
Since 2020, 4 proprietary Chinese medicines for the respiratory system have been approved for listing.
Jiangsu Kangyuan Pharmaceutical's Yinqiao Qingre Tablets, Hubei Youersheng Pharmaceutical's Tianxing Cough Paste, and Shenzhen Sanshun Pharmaceutical's Caohong Capsules have submitted new drugs for listing.
All applications are under review and approval.
Chinese patent medicines for respiratory system are selling well in Beijing! The market share of the three major sub-categories exceeds 90%
Chinese patent medicines for respiratory system are selling well in Beijing! The market share of the three major sub-categories exceeds 90% Quarterly sales of proprietary Chinese medicines for respiratory system in public hospitals in key cities in recent years
Source: Competitive pattern of proprietary Chinese medicine terminals in public hospitals in key cities
According to data from Mi Nei.
com, in recent years, the sales of Chinese patent medicines for the respiratory system of public hospitals in key cities have exceeded 3.
5 billion yuan.
In 2020, affected by the epidemic, it will drop 20% year-on-year.
In terms of quarterly sales trends, both Q1 and Q2 fell more than 25% year-on-year in 2020.
The market gradually recovered in the second half of the year.
Q3 fell 15.
96% year-on-year, and Q4 has been significantly reduced to 4.
59%.
com, in recent years, the sales of Chinese patent medicines for the respiratory system of public hospitals in key cities have exceeded 3.
5 billion yuan.
In 2020, affected by the epidemic, it will drop 20% year-on-year.
In terms of quarterly sales trends, both Q1 and Q2 fell more than 25% year-on-year in 2020.
The market gradually recovered in the second half of the year.
Q3 fell 15.
96% year-on-year, and Q4 has been significantly reduced to 4.
59%.
The urban pattern of Chinese patent medicines for the respiratory system of public hospitals in key cities in 2020
Source: Competitive pattern of proprietary Chinese medicine terminals in public hospitals in key cities
From the perspective of the urban structure, Beijing's sales are thriving, exceeding 600 million yuan; Chengdu and Harbin both exceed 400 million yuan.
From the perspective of sub-categories, the three major sub-categories of heat-clearing and detoxifying medications, cough-relieving and anti-asthmatic medications, and cold medications have a combined market share of more than 95%.
From the perspective of sub-categories, the three major sub-categories of heat-clearing and detoxifying medications, cough-relieving and anti-asthmatic medications, and cold medications have a combined market share of more than 95%.
Yangtze River, Yiling.
.
.
14 exclusive products "seize" TOP20
Yangtze River, Yiling. .
.
14 exclusive products "seize" TOP20
.
.
14 exclusive products "seize" TOP20
Top 10 Chinese patent medicine products for respiratory system in public hospitals in key cities in 2020
Source: Competitive pattern of proprietary Chinese medicine terminals in public hospitals in key cities
Among the TOP20 products, six products have sales of more than 100 million yuan.
Suhuang Cough Capsules, Xuebijing Injection, Pudilan Anti-inflammatory Oral Liquid, Lianhua Qingwen Granules and other 14 are exclusive products, involving Yangtze River Beijing Haiyan Pharmaceutical, Tianjin Hongri Pharmaceutical, Jichuan Pharmaceutical Group, Beijing Ling Pharmaceutical and many other enterprises .
In terms of growth rate, Shuanghuanglian Oral Liquid and Lianhua Qingwen Granules both increased by more than 50% year-on-year.
It is worth mentioning that Shuanghuanglian oral liquid, Shufeng Jiedu capsule, cough and asthma syrup are all new products on the list.
Enterprise business enterpriseSuhuang Cough Capsules, Xuebijing Injection, Pudilan Anti-inflammatory Oral Liquid, Lianhua Qingwen Granules and other 14 are exclusive products, involving Yangtze River Beijing Haiyan Pharmaceutical, Tianjin Hongri Pharmaceutical, Jichuan Pharmaceutical Group, Beijing Ling Pharmaceutical and many other enterprises .
In terms of growth rate, Shuanghuanglian Oral Liquid and Lianhua Qingwen Granules both increased by more than 50% year-on-year.
It is worth mentioning that Shuanghuanglian oral liquid, Shufeng Jiedu capsule, cough and asthma syrup are all new products on the list.
2020 Top 10 Chinese Patent Medicine Brands for Respiratory System in Public Hospitals in Key Cities
Source: Competitive pattern of proprietary Chinese medicine terminals in public hospitals in key cities
The total market share of TOP20 brands exceeds 60%.
Among them, Suhuang Cough Capsules from Yangtze River Beijing Haiyan Pharmaceutical, Xiyanping Injection from Jiangxi Qingfeng Pharmaceutical, and Tanreqing Injection from Shanghai Kaibao Pharmaceutical rank among the top three.
.
Among them, Suhuang Cough Capsules from Yangtze River Beijing Haiyan Pharmaceutical, Xiyanping Injection from Jiangxi Qingfeng Pharmaceutical, and Tanreqing Injection from Shanghai Kaibao Pharmaceutical rank among the top three.
.
Sales of Shuanghuanglian Oral Liquid in Public Hospitals in Key Cities in Recent Years
Source: Competitive pattern of proprietary Chinese medicine terminals in public hospitals in key cities
Shuanghuanglian oral liquid has the effects of dispelling wind, relieving the surface, clearing heat and detoxifying, and is used for colds caused by exogenous wind-heat, such as fever, cough and sore throat.
According to data from Meinenet, the sales of Shuanghuanglian oral liquid in public hospitals in key cities have increased rapidly in the past two years , and the year-on-year growth rate will reach nearly 70% in 2020.
There are 12 companies with production approvals for this product.
Among them, Heilongjiang Regal Pharmaceutical has the largest market share, exceeding 60%, and Henan Tailong Pharmaceutical ranks second.
Hospital hospital hospitalAccording to data from Meinenet, the sales of Shuanghuanglian oral liquid in public hospitals in key cities have increased rapidly in the past two years , and the year-on-year growth rate will reach nearly 70% in 2020.
There are 12 companies with production approvals for this product.
Among them, Heilongjiang Regal Pharmaceutical has the largest market share, exceeding 60%, and Henan Tailong Pharmaceutical ranks second.
Sales of Lianhua Qingwen Granules in Public Hospitals in Key Cities in Recent Years
Source: Competitive pattern of proprietary Chinese medicine terminals in public hospitals in key cities
Lianhua Qingwen Granules is an exclusive product of Ling Pharmaceutical.
According to data from Minaiwang, the sales of Lianhua Qingwen Granules in public hospitals in key cities have maintained a growth rate of more than 20% in recent years, and will reach a new high in 2020.
A few days ago, Yiling Pharmaceutical disclosed its performance in 2020, with revenue of 8.
78 billion yuan, a year-on-year increase of 50.
76%; net profit of 1.
219 billion yuan, a year-on-year increase of 100.
95%.
Yiling Pharmaceutical pointed out in the annual report that Lianhua Qingwen products played an important role in the prevention and control of the epidemic, which not only drove the substantial increase in product sales, but also increased the coverage of the blank market structurally, and the brand influence was significantly improved.
With strong market demand, it has become a regular backup drug for many families, providing impetus for its future growth.
At the same time, Lianhua Qingwen has obtained approvals and achieved sales in more than 20 countries and regions.
According to data from Minaiwang, the sales of Lianhua Qingwen Granules in public hospitals in key cities have maintained a growth rate of more than 20% in recent years, and will reach a new high in 2020.
A few days ago, Yiling Pharmaceutical disclosed its performance in 2020, with revenue of 8.
78 billion yuan, a year-on-year increase of 50.
76%; net profit of 1.
219 billion yuan, a year-on-year increase of 100.
95%.
Yiling Pharmaceutical pointed out in the annual report that Lianhua Qingwen products played an important role in the prevention and control of the epidemic, which not only drove the substantial increase in product sales, but also increased the coverage of the blank market structurally, and the brand influence was significantly improved.
With strong market demand, it has become a regular backup drug for many families, providing impetus for its future growth.
At the same time, Lianhua Qingwen has obtained approvals and achieved sales in more than 20 countries and regions.
According to the data, in the fourth to eighth editions of the "Diagnosis and Treatment Plan for Pneumonia Infected by New Coronavirus", it is recommended to take the Chinese patent medicine Lianhua Qingwen for the prevention and treatment of patients with fatigue and fever during the medical observation period.
More than 20 provinces and cities such as Hubei, Guangzhou, Zhejiang, Shandong, Hebei and other provinces and cities have successively released new coronary pneumonia prevention and treatment plans, and Lianhua Qingwen is also recommended.
The "three medicines and three prescriptions" screened for effective drugs for the treatment of new coronary pneumonia in Chinese medicine include Lianhua Qingwen capsules/granules.
In April 2020, Lianhua Qingwen capsules/granules were approved to add new indications of "New Coronavirus Pneumonia Light and Common" on the basis of the original approved indications.
Medicine Medicine MedicineMore than 20 provinces and cities such as Hubei, Guangzhou, Zhejiang, Shandong, Hebei and other provinces and cities have successively released new coronary pneumonia prevention and treatment plans, and Lianhua Qingwen is also recommended.
The "three medicines and three prescriptions" screened for effective drugs for the treatment of new coronary pneumonia in Chinese medicine include Lianhua Qingwen capsules/granules.
In April 2020, Lianhua Qingwen capsules/granules were approved to add new indications of "New Coronavirus Pneumonia Light and Common" on the basis of the original approved indications.
4 products have been approved since 2020 ! 3 major new drugs launched an impact
4 products have been approved since 2020 ! 3 major new drugs launched an impact Review of applications for the listing of Chinese patent medicines for respiratory system since 2020
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since 2020, a total of 4 Chinese patent medicines for respiratory system have been approved for production.
In May 2020, Yiling Pharmaceutical’s Lianhua Qingke Tablets was approved to be marketed.
This product is a new class of 6.
1 new Chinese medicine for the treatment of acute tracheal-bronchitis developed under the guidance of TCM collateral disease theory.
The cumulative R&D investment exceeds 20 million yuan; In December, Lianhua Qingke Tablets were included in the 2020 National Medical Insurance Catalogue for the first time through medical insurance negotiations.
In March of this year, the State Food and Drug Administration approved the listing of Qingfei Paidu Granules from the Institute of Basic Clinical Medicine of Chinese Academy of Chinese Medical Sciences, Huashibaidu Granules of Guangdong Yifang Pharmaceutical, and Xuanfeibaidu Granules of Shandong Buchang Pharmaceutical through special approval procedures.
.
The three products are the results of the effective prescriptions Qingfei Paidu Decoction, Huashi Baidu Recipe, and Xuanfei Baidu Recipe screened by many academicians and experts in the anti-epidemic clinical front-line in Wuhan.
They are also the first time after the reform of Chinese medicine registration classification according to the "Chinese medicine registration classification and Application materials requirements" "Class 3.
2 other traditional Chinese medicine compound preparations derived from ancient classic prescriptions" review and approval varieties.
Chinese Medicine Chinese Medicine Chinese MedicineIn May 2020, Yiling Pharmaceutical’s Lianhua Qingke Tablets was approved to be marketed.
This product is a new class of 6.
1 new Chinese medicine for the treatment of acute tracheal-bronchitis developed under the guidance of TCM collateral disease theory.
The cumulative R&D investment exceeds 20 million yuan; In December, Lianhua Qingke Tablets were included in the 2020 National Medical Insurance Catalogue for the first time through medical insurance negotiations.
In March of this year, the State Food and Drug Administration approved the listing of Qingfei Paidu Granules from the Institute of Basic Clinical Medicine of Chinese Academy of Chinese Medical Sciences, Huashibaidu Granules of Guangdong Yifang Pharmaceutical, and Xuanfeibaidu Granules of Shandong Buchang Pharmaceutical through special approval procedures.
.
The three products are the results of the effective prescriptions Qingfei Paidu Decoction, Huashi Baidu Recipe, and Xuanfei Baidu Recipe screened by many academicians and experts in the anti-epidemic clinical front-line in Wuhan.
They are also the first time after the reform of Chinese medicine registration classification according to the "Chinese medicine registration classification and Application materials requirements" "Class 3.
2 other traditional Chinese medicine compound preparations derived from ancient classic prescriptions" review and approval varieties.
In addition, Jiangsu Kangyuan Pharmaceutical's Yinqiao Qingre Tablets, Hubei Youersheng Pharmaceutical's Tianxing Cough Paste, and Shenzhen Sanshun Pharmaceutical's Caohong Capsules submitted new drug listing applications for approval.
Source: Mi Nei.
com database, announcement of listed companies
Source: Mi Nei. com database, announcement of listed companies
com database, announcement of listed companies
Note: The Chinese patent medicine terminal competition pattern database of public hospitals in key cities of Minaiwang is a sales database that continuously monitors the entire category of Chinese patent medicines based on the pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement data of Chinese patent medicines from all public hospitals in 9 major cities .
The data covers 13 categories.
More than 74 sub-categories, 3600+ common name varieties.
The database is updated quarterly to provide timely feedback on the impact of policy changes on products, and analyze the sales, market shares, sales trends and development laws of various categories and varieties of Chinese patent medicines in 9 cities in all categories in an all-round and multi-dimensional manner.
pharmnet. com.
cn/news/yyzb/" target="_blank">procurement data of Chinese patent medicines from all public hospitals in 9 major cities .
The data covers 13 categories.
More than 74 sub-categories, 3600+ common name varieties.
The database is updated quarterly to provide timely feedback on the impact of policy changes on products, and analyze the sales, market shares, sales trends and development laws of various categories and varieties of Chinese patent medicines in 9 cities in all categories in an all-round and multi-dimensional manner.
com.
cn/news/yyzb/" target="_blank">Procurementpharmnet.
com.
cn/news/yyzb/" target="_blank"> Procurement Procurement
